Cargando…

Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy

PURPOSE: The prognostic value of PSMA intensity on PSMA PET/CT due to underlying biology and subsequent clinical implications is an emerging topic of interest. We sought to investigate whether primary tumour PSMA PET intensity contributes to pre- and post-operative prediction of oncological outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Roberts, Matthew J., Morton, Andrew, Papa, Nathan, Franklin, Anthony, Raveenthiran, Sheliyan, Yaxley, William J., Coughlin, Geoffrey, Gianduzzo, Troy, Kua, Boon, McEwan, Louise, Wong, David, Delahunt, Brett, Egevad, Lars, Samaratunga, Hemamali, Brown, Nicholas, Parkinson, Robert, Emmett, Louise, Yaxley, John W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250456/
https://www.ncbi.nlm.nih.gov/pubmed/35298693
http://dx.doi.org/10.1007/s00259-022-05756-2
_version_ 1784739816206761984
author Roberts, Matthew J.
Morton, Andrew
Papa, Nathan
Franklin, Anthony
Raveenthiran, Sheliyan
Yaxley, William J.
Coughlin, Geoffrey
Gianduzzo, Troy
Kua, Boon
McEwan, Louise
Wong, David
Delahunt, Brett
Egevad, Lars
Samaratunga, Hemamali
Brown, Nicholas
Parkinson, Robert
Emmett, Louise
Yaxley, John W.
author_facet Roberts, Matthew J.
Morton, Andrew
Papa, Nathan
Franklin, Anthony
Raveenthiran, Sheliyan
Yaxley, William J.
Coughlin, Geoffrey
Gianduzzo, Troy
Kua, Boon
McEwan, Louise
Wong, David
Delahunt, Brett
Egevad, Lars
Samaratunga, Hemamali
Brown, Nicholas
Parkinson, Robert
Emmett, Louise
Yaxley, John W.
author_sort Roberts, Matthew J.
collection PubMed
description PURPOSE: The prognostic value of PSMA intensity on PSMA PET/CT due to underlying biology and subsequent clinical implications is an emerging topic of interest. We sought to investigate whether primary tumour PSMA PET intensity contributes to pre- and post-operative prediction of oncological outcomes following radical prostatectomy. METHODS: We performed a retrospective cohort study of 848 men who underwent all of multiparametric MRI (mpMRI), transperineal prostate biopsy, and (68) Ga-PSMA PET/CT prior to radical prostatectomy. PSMA intensity, quantified as maximum standard uptake value (SUVmax), and other clinical variables were considered relative to post-operative biochemical recurrence-free survival (BRFS) using Cox regression and Kaplan–Meier analysis. RESULTS: After a median follow-up of 41 months, 219 events occurred; the estimated 3-year BRFS was 79% and the 5-year BRFS was 70%. Increasing PSMA intensity was associated with less favourable BRFS overall (Log rank p < 0.001), and within subgroups of Gleason score category (Log rank p < 0.03). PSMA intensity was significantly associated with shorter time to biochemical recurrence, after adjusting for pre-operative (HR per 5-unit SUVmax increase = 1.15) and post-operative (HR per 5-unit SUVmax increase = 1.10) parameters. CONCLUSION: These results in a large series of patients confirm PSMA intensity to be a novel, independent prognostic factor for BRFS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-022-05756-2.
format Online
Article
Text
id pubmed-9250456
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-92504562022-07-04 Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy Roberts, Matthew J. Morton, Andrew Papa, Nathan Franklin, Anthony Raveenthiran, Sheliyan Yaxley, William J. Coughlin, Geoffrey Gianduzzo, Troy Kua, Boon McEwan, Louise Wong, David Delahunt, Brett Egevad, Lars Samaratunga, Hemamali Brown, Nicholas Parkinson, Robert Emmett, Louise Yaxley, John W. Eur J Nucl Med Mol Imaging Short Communication PURPOSE: The prognostic value of PSMA intensity on PSMA PET/CT due to underlying biology and subsequent clinical implications is an emerging topic of interest. We sought to investigate whether primary tumour PSMA PET intensity contributes to pre- and post-operative prediction of oncological outcomes following radical prostatectomy. METHODS: We performed a retrospective cohort study of 848 men who underwent all of multiparametric MRI (mpMRI), transperineal prostate biopsy, and (68) Ga-PSMA PET/CT prior to radical prostatectomy. PSMA intensity, quantified as maximum standard uptake value (SUVmax), and other clinical variables were considered relative to post-operative biochemical recurrence-free survival (BRFS) using Cox regression and Kaplan–Meier analysis. RESULTS: After a median follow-up of 41 months, 219 events occurred; the estimated 3-year BRFS was 79% and the 5-year BRFS was 70%. Increasing PSMA intensity was associated with less favourable BRFS overall (Log rank p < 0.001), and within subgroups of Gleason score category (Log rank p < 0.03). PSMA intensity was significantly associated with shorter time to biochemical recurrence, after adjusting for pre-operative (HR per 5-unit SUVmax increase = 1.15) and post-operative (HR per 5-unit SUVmax increase = 1.10) parameters. CONCLUSION: These results in a large series of patients confirm PSMA intensity to be a novel, independent prognostic factor for BRFS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-022-05756-2. Springer Berlin Heidelberg 2022-03-17 2022 /pmc/articles/PMC9250456/ /pubmed/35298693 http://dx.doi.org/10.1007/s00259-022-05756-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Short Communication
Roberts, Matthew J.
Morton, Andrew
Papa, Nathan
Franklin, Anthony
Raveenthiran, Sheliyan
Yaxley, William J.
Coughlin, Geoffrey
Gianduzzo, Troy
Kua, Boon
McEwan, Louise
Wong, David
Delahunt, Brett
Egevad, Lars
Samaratunga, Hemamali
Brown, Nicholas
Parkinson, Robert
Emmett, Louise
Yaxley, John W.
Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy
title Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy
title_full Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy
title_fullStr Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy
title_full_unstemmed Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy
title_short Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy
title_sort primary tumour psma intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250456/
https://www.ncbi.nlm.nih.gov/pubmed/35298693
http://dx.doi.org/10.1007/s00259-022-05756-2
work_keys_str_mv AT robertsmatthewj primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy
AT mortonandrew primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy
AT papanathan primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy
AT franklinanthony primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy
AT raveenthiransheliyan primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy
AT yaxleywilliamj primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy
AT coughlingeoffrey primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy
AT gianduzzotroy primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy
AT kuaboon primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy
AT mcewanlouise primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy
AT wongdavid primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy
AT delahuntbrett primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy
AT egevadlars primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy
AT samaratungahemamali primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy
AT brownnicholas primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy
AT parkinsonrobert primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy
AT emmettlouise primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy
AT yaxleyjohnw primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy